Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alvotech Taps Equity Financing As Venture Bears Fruit In Saudi Arabia

Icelandic Firm Expects To Bring In North Of $135m Via Private Placement

Executive Summary

Alvotech has once again raised more than $100m in financing, the second time in a matter of months, via a private placement involving what it expects to be previously issued treasury shares held by one of its subsidiaries.

You may also be interested in...



Alvotech Lines Up FDA Inspection Ahead Of Adalimumab Action

Alvotech has secured a US FDA reinspection of its Reykjavik plant in March, ahead of the agency’s April goal date for action on the firm’s pending application for a high-concentration, interchangeable adalimumab biosimilar rival to Humira.

Alvotech Targets MENA In Multi-Biosimilar Commercialization Deal

Three firms across Europe and North Africa sign to sell Alvotech biosimilar candidates in 19 MENA countries as the Icelandic developer shifts focus from R&D to global commercialization.

Eylea Race Continues To Heat Up With Formycon Unveiling Early Positive Data

Weeks after Coherus BioSciences put pen to paper on a deal to bring in Formycon’s FYB203 proposed biosimilar to Eylea (aflibercept), the candidate has shown positive efficacy and safety data, according to preliminary Phase III trial results.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB152459

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel